New Zealand Data Sheet

**DermAssist**
Hydrocortisone 1% Cream

**Name of the medicine**
DermAssist Cream contains hydrocortisone 1% w/w.

**Description**
DermAssist Cream contains hydrocortisone, white vaseline, liquid paraffin, cetostearyl alcohol, cetomacrogol 1000, chlorocresol, purified water.

Hydrocortisone is a corticosteroid.

**Structural formula:**

![Structural formula of hydrocortisone](image)

CAS No. 50-23-7

Chemical name: 11β,17α,21-trihydroxypregn-4-ene-3,20-dione.

Empirical formula: C21H30O5.

**Pharmacology**
DermAssist Cream contains hydrocortisone. Hydrocortisone has anti-inflammatory, anti-eczematous, anti-allergic and anti-pruritic properties.

Metabolism: Hydrocortisone is metabolised in the liver most likely by reduction of the 5,6 double bond and the C3 and C20 keto groups. The resultant hydroxy derivatives are then conjugated with glucuronic acid. Cortisone, an 11-keto-steroid is formed from hydrocortisone; the 11-keto-steroids are then reduced and conjugated to yield glucuronide metabolites. A small percentage of hydrocortisone is converted to the 17-keto-steroid. The C21 hydroxyl group is conjugated with sulphate.

Excretion: When radioactive-carbon, ring-labelled steroids are injected intravenously in man, most of the radioisotope is recovered in the urine within 72 hours. Neither biliary nor faecal excretion is of any quantitative importance in man. It has been estimated that the liver metabolises at least 70% of the hydrocortisone secreted.

Hydrocortisone is absorbed through the skin allowing penetration to the deeper layers. The extent of absorption is greater for inflamed skin and other skin conditions such as eczema and psoriasis. Absorption is also greater in areas such as the ear, scrotum, axillae, face and scalp. Absorption is aided by occlusive dressings due to
the resulting hydration of the skin. Once absorbed, the pharmacokinetics are similar to systemic steroids. DermAssist should not be used under bandages or dressings except on medical advice.

**Indications**

DermAssist Cream is indicated for topical application for the temporary relief of symptoms associated with acute and chronic corticosteroid responsive conditions including, minor skin irritations, itching and rashes due to eczema, dermatitis, contact dermatitis (such as rashes due to cosmetics and jewellery), psoriasis, anogenital pruritus and sunburn.

**Contraindications**

Acne.

Hypersensitivity to any of the ingredients.

Do not use in the eye.

Like all other topical corticosteroids, DermAssist is contraindicated in skin infections and infestations such as chicken pox, herpes and other viral infections.

Hydrocortisone may mask signs of infection. If any infection is present, an appropriate anti-infective agent should be used first. DermAssist may be used to reduce inflammation but if a favourable response does not occur promptly then use of the product should be discontinued until the infection has been adequately controlled.

If any skin irritation develops discontinue use and treat appropriately. If extensive areas are treated, or if occlusive dressings are used, the possibility also exists for increased systemic absorption and this could in turn lead to the depression of the hypothalamo-pituitary-adrenal axis. In all such patients it is essential to monitor adrenal function at regular intervals.

**Precautions**

Long-term continuous topical therapy should be avoided where possible, particularly in children, as adrenal suppression can occur (even without occlusion).

As with other topical corticosteroids, when extensive areas are treated, sufficient systemic absorption may occur to produce the features of hypercorticalism. This effect is more likely to result if occlusive dressings are used or if treatment is prolonged. Rarely, local atrophy or striae may occur after prolonged treatment. This must be borne in mind when treating conditions such as severe eczema and seborrhoeic dermatitis. If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye as glaucoma may result.

Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions that have become infected.

Any spread of the infection requires withdrawal of corticosteroid therapy and systemic administration of antimicrobial agents. Bacterial infection is encouraged by the warm, moist conditions associated by occlusive dressings, so the skin should be cleansed prior to a fresh dressing being applied.
Patients in whom there is a risk of increased systemic absorption should be regularly evaluated for evidence of hypothalmic-pituitary-adrenal (HPA) axis suppression by using urinary free cortisol (hydrocortisone) tests and monitoring morning plasma cortisol levels.

If there is evidence of suppression, attempts should be made to withdraw the drug or reduce the frequency of application. If hypersensitivity occurs, stop application and institute appropriate therapy. If irritation occurs, discontinue use. Systemic absorption of topical corticosteroids will be increased if extensive body surface areas are treated or if occlusion is used. Suitable precautions should be taken under these conditions or when long-term use is anticipated.

Hydrocortisone may mask signs of infection. If any infection is present, an appropriate anti-infective agent should be used first. DermAssist may be used to reduce inflammation but if a favourable response does not occur promptly then use of the product should be discontinued until the infection has been adequately controlled.

Use of the product near the eyes should be avoided. If any skin irritation develops discontinue use and treat appropriately. If extensive areas are treated, or if occlusive dressings are used, the possibility also exists of increased systemic absorption and this could in turn lead to the depression of the hypothalamo-pituitary-adrenal axis. In all such patients it is essential to monitor adrenal function at regular intervals.

**Use in pregnancy**

Category A: Drugs which have been taken by a large number of pregnant women and women of child bearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus having been observed.

**Use in lactation**

It is not known whether sufficient absorption of topical corticosteroids takes place to be excreted in breast milk. The potential benefits should be weighed against possible hazards to the breastfeeding infant.

**Use in children**

The risk of systemic absorption, and hence systemic toxicity, is greater in children due to a larger skin surface to body weight ratio than adults. The preparation is not recommended for use in children under 2 years of age except on the advice of a doctor.

**Interactions with other medicines**

No interactions known.

**Adverse Effects**

After the application of DermaAssist a slight stinging sensation may occasionally be noticed. This transient symptom is most likely to disappear after several applications. The following adverse effects have been reported with topical steroids: burning; itching; irritation; skin atrophy; secondary infection; dryness; acneform eruptions and
hypo-pigmentation. Treatment should be chiefly symptomatic and administration of
the steroid should be discontinued.

Intolerance to the occlusive dressing (Miliary eruptions, folliculitis) may be expected
to be observed, as with other corticosteroids. In such cases the use of an occlusive
dressing should be discontinued. DermAssist should not be used under bandages
or dressings except on medical advice.

Use of the steroid may also need to be reduced or discontinued as local atrophy and
striae of the skin may be observed. In long-term treatment of extensive skin areas
with occlusive dressings, one should bear in mind the possibility of inhibition of
adrenal function. Therefore, adrenal function should be monitored under these
circumstances.

**Dosage and Administration**

Apply a thin layer to the affected skin three to four times a day as required. Once the
inflammation has subsided the frequency of use may be reduced.

DermAssist should not be used under bandages or dressings except on medical
advice.

**Overdosage**

Percutaneous absorption of corticosteroids may occur, especially under occlusive
conditions. The following adverse effects have been reported with topical steroids:
burning; itching; irritation; skin atrophy; secondary infection; dryness; acne form
eruptions and hypo-pigmentation. Treatment should be chiefly symptomatic and
administration of the steroid should be discontinued.

**Presentation**

15g and 30g tubes.

**Storage**

Store at or below 25°C.

**Medicine Classification**

Pharmacist Only Medicine

**Name and Address of Sponsor**

Teva Pharma (New Zealand) Limited
PO Box 128 244
Remuera
Auckland 1541
Telephone: 0800 800 097

**Date of Preparation**

21 March 2017